Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
about
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsMetronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaGene therapy for brain tumors: basic developments and clinical implementationO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsExtended-schedule dose-dense temozolomide in refractory gliomasShort delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II studyAntiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionPhase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.APNG as a prognostic marker in patients with glioblastoma.Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomideMesenchymal migration as a therapeutic target in glioblastoma.Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade gliomaCritical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerationsThe expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapyRegulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Surgery of highly eloquent gliomas primarily assessed as non-resectable: risks and benefits in a cohort study.Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional resultsChemoresistance of glioblastoma cancer stem cells--much more complex than expected.Motivating the additional use of external validity: examining transportability in a model of glioblastoma multiforme.Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed GlioblastomaOverexpression of DNA methyltransferase 1 (DNMT1) protein in astrocytic tumour and its correlation with O6-methylguanine-DNA methyltransferase (MGMT) expressionO6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomasHsp27 (HSPB1): a possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas.BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.Selection of chemotherapy for glioblastoma expressing O(6)-methylguanine-DNA methyltransferaseMGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study.New developments in the treatment of malignant gliomas.Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
P2860
Q24607903-30B1E4ED-C171-4927-91AA-B218FE1FEC33Q26753070-766D231F-E1F7-45F9-A2DA-ACC7B0E924E7Q26829086-7A5F181E-F73F-433E-823A-D1386121722AQ26853112-39357C57-11AF-4525-8D2A-6903828F4B92Q33385736-77B95571-2A09-4B8D-B61D-A91CAD3F1494Q33396435-1E475284-68B4-4840-A382-72736F4DD8C5Q33416431-D0D911E6-A7D1-4618-8226-EF6A54932538Q33499541-6C638EAF-09A4-4EAA-9FE6-EA056145A730Q33551268-ED325113-E35B-4D4B-9119-8C85FE65E0B2Q33713587-EF66FC02-0BE3-4703-AF63-C9CBD3A8FC21Q33804528-4219F783-8670-4C6C-A673-DBC9D70BDF1AQ33828114-51FAFEBD-4E28-4467-A1E7-ECD14A6DC334Q33852894-BF2F6C0F-9F38-4AE2-8124-3AF6FD248F46Q33911224-7624A05E-0054-462F-8D7D-945EC130D96CQ34000287-A1C21A7C-D9C1-4192-8518-F57ECE2DC4DEQ34002994-57B25314-B61A-430F-B0E4-635970D6C8D9Q34062033-A790BCEE-E0ED-451B-8F42-475B70EB4377Q34418437-5F77B5C5-019F-4D16-9A84-17698697D61FQ34467881-A89DA211-2C8B-4750-BB86-E8D855ADD056Q34478948-7597E736-9657-4EC3-BC96-723D85AF78A6Q34572229-0310C360-047A-43A0-BB93-FCA96D9793E2Q34722521-ADE093AD-6C2D-42BC-A652-4571CA82E030Q34809620-B32EF5DD-CA93-43A4-BBFC-29782744AFFAQ35001754-88D3CFCC-1D82-4E65-9C23-2EBE52FF33D2Q35050383-6C497197-8F83-4174-865A-535FEFBE8970Q35521316-6258D9A7-5640-45E0-AB3F-3D451121322AQ35570399-CD728CC5-6E74-47C6-9132-5298DF027931Q35785924-F4F7171E-361D-4D7C-AB37-70BD5C04D806Q35862544-5C9959DB-84EF-496B-A86D-F7985411111FQ35918897-4F10CE34-AC7C-4AFB-AF10-DE1761C3217DQ36096925-74E7D980-1F0F-451B-9309-2CC45B9C6C4AQ36288503-8971E965-185A-4D63-9E9F-50F3A54C1D70Q36309862-9684B218-A48B-4A9D-9A34-64C5A0C1D24DQ36347256-11061F7E-9D37-4D34-93C4-809F9410FE29Q36375392-7B44F553-31DE-4D53-9FAC-14E5A4B06CF1Q36552798-5BC71EAC-3F5F-4435-B290-00B55FDA3876Q36627170-BB30217A-7412-41E5-A1AE-BA8EEEC2ED64Q36696480-42624216-9FAB-499C-B7E0-CB1D0AC87219Q36972696-F4C46F50-1952-40D2-AD2E-CDA0077E1F2AQ37027202-26514A2E-CF86-4DE5-ABB8-7989F87FE5A6
P2860
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@ast
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@en
type
label
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@ast
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@en
prefLabel
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@ast
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@en
P2093
P50
P356
P1476
Correlation between O6-methylg ...... with neoadjuvant temozolomide.
@en
P2093
Diane Braguer
Henry Dufour
Maryline Barrié
Nathalie Eudes
Philippe Metellus
Pierre-Marie Martin
Sophie Lancelot
Stephane Fuentes
Xavier Muracciole
P304
P356
10.1200/JCO.2006.07.4807
P407
P577
2007-04-01T00:00:00Z